Cargando…
Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling
BACKGROUND: We have shown previously that whereas overexpression of human epidermal growth factor receptor (HER)1, HER2 and HER3 is associated with poor prognosis in breast cancer, HER4 is associated with a good prognosis. Cell proliferation is a key component of aggressive cancers and is driven by...
Autores principales: | Tovey, Sian M, Witton, Caroline J, Bartlett, John MS, Stanton, Peter D, Reeves, Jonathan R, Cooke, Timothy G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC400680/ https://www.ncbi.nlm.nih.gov/pubmed/15084248 http://dx.doi.org/10.1186/bcr783 |
Ejemplares similares
-
HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4
por: Tovey, Sian M, et al.
Publicado: (2006) -
Comparison of bromodeoxyuridine and proliferating cell nuclear antigen labeling in gastric carcinoma.
por: Kang, S. M., et al.
Publicado: (1994) -
Measurement of cell kinetics in cervical tumours using bromodeoxyuridine.
por: Bolger, B. S., et al.
Publicado: (1993) -
Cell proliferation in the Drosophila adult brain revealed by clonal analysis and bromodeoxyuridine labelling
por: von Trotha, Jakob W, et al.
Publicado: (2009) -
Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labelling.
por: Tinnemans, M. M., et al.
Publicado: (1993)